Introduction
The modern management of Type 2 Diabetes Mellitus (T2DM) requires a multifaceted approach targeting insulin resistance, pancreatic dysfunction, and hepatic glucose production. SEIZMET GP 2 by Steris Healthcare Pvt. Ltd. is a scientifically backed triple drug combination that effectively combats these challenges. With the power of glimepiride metformin and pioglitazone tablets, SEIZMET GP 2 offers better glycemic control and improved long-term outcomes in diabetic patients.This fixed-dose combination is designed for patients who are inadequately controlled with monotherapy or dual therapy, helping them avoid insulin initiation and enhancing treatment adherence.
Chemical Composition
Each tablet of SEIZMET GP 2 contains:
Glimepiride – 2 mg
Metformin Hydrochloride SR – 500 mg
Pioglitazone – 15 mg
These three medications work in synergy to offer comprehensive antihyperglycemic effects, attacking the core defects in T2DM physiology.
Formulation Details
Glimepiride: Immediate-release
Metformin SR: Sustained-release for smoother plasma concentration over 24 hours
Pioglitazone: Immediate-release, ensuring rapid insulin sensitization
Tablet Design: Film-coated, easy to swallow, once-daily dosing
The sustained-release formulation of Metformin helps minimize gastrointestinal irritation, a common concern in diabetic treatment.
Mechanism of Action
Glimepiride: A sulfonylurea that stimulates pancreatic β-cells to release insulin.
Metformin: A biguanide that decreases hepatic glucose production and increases insulin sensitivity.
Pioglitazone: A thiazolidinedione that improves peripheral glucose uptake and reduces insulin resistance.
Together, the glimepiride metformin and pioglitazone combination provides comprehensive glycemic control by targeting different physiological pathways.
Uses and Indications
SEIZMET GP 2 is indicated for the management of Type 2 Diabetes Mellitus, particularly in:
Patients inadequately controlled on dual therapy
Those with moderate to severe insulin resistance
Patients who require intensive glycemic control without insulin
Individuals with cardiometabolic syndrome, where pioglitazone offers additional lipid-modifying benefits
Dosage and Administration
Standard Dose: 1 tablet once daily with meals (preferably breakfast)
Can be titrated based on blood glucose levels and patient response
Regular monitoring of fasting blood glucose, postprandial glucose, and HbA1c is recommended
Note: Elderly patients or those with renal impairment may require dose adjustments.
Efficacy and Clinical Evidence
Clinical trials have consistently shown that glimepiride metformin and pioglitazone tablets are more effective than monotherapy or dual therapy in lowering HbA1c.
Clinical Highlights:
HbA1c Reduction: Up to 2.5% in patients with poor baseline control
Improved insulin sensitivity and beta-cell function preservation
Delayed need for insulin therapy in long-term diabetes management
Weight-neutral or mild weight gain with pioglitazone use, offset by metformin’s weight-stabilizing effect
HbA1c Reduction: Up to 2.5% in patients with poor baseline control
Improved insulin sensitivity and beta-cell function preservation
Delayed need for insulin therapy in long-term diabetes management
Weight-neutral or mild weight gain with pioglitazone use, offset by metformin’s weight-stabilizing effect
Pioglitazone also exhibits cardioprotective and lipid-lowering properties, reducing triglycerides and improving HDL-C levels.
Side Effects and Safety Profile
Common Side Effects:
Hypoglycemia (mainly from glimepiride)
Gastrointestinal issues like bloating or diarrhea (due to metformin)
Weight gain, edema, or fluid retention (pioglitazone)
Hypoglycemia (mainly from glimepiride)
Gastrointestinal issues like bloating or diarrhea (due to metformin)
Weight gain, edema, or fluid retention (pioglitazone)
Rare Adverse Effects:
Lactic acidosis (rare but serious, mostly linked to metformin)
Congestive heart failure (associated with thiazolidinediones)
Hepatic dysfunction (monitor liver enzymes regularly)
Lactic acidosis (rare but serious, mostly linked to metformin)
Congestive heart failure (associated with thiazolidinediones)
Hepatic dysfunction (monitor liver enzymes regularly)
Despite these, SEIZMET GP 2 remains well-tolerated in most patients, especially with appropriate dose titration and monitoring.
Contraindications and Precautions
Contraindicated in:
Type 1 diabetes or diabetic ketoacidosis
Severe renal or hepatic impairment
Heart failure (NYHA Class III or IV)
History of bladder cancer (pioglitazone caution)
Type 1 diabetes or diabetic ketoacidosis
Severe renal or hepatic impairment
Heart failure (NYHA Class III or IV)
History of bladder cancer (pioglitazone caution)
Precautions:
Regular monitoring of renal, hepatic, and cardiac function
Caution in elderly, alcoholics, or malnourished individuals
Avoid use during pregnancy or breastfeeding
Drug Interactions
Certain drugs may interact with SEIZMET GP 2, including:
NSAIDs and sulfonylureas: May potentiate hypoglycemia
Corticosteroids and diuretics: May increase blood glucose
ACE inhibitors, insulin, or GLP-1 agonists: May enhance the hypoglycemic effect
Alcohol: Can increase the risk of lactic acidosis
A detailed medication history is essential before initiating therapy.
Warnings and Regulatory Status
Pioglitazone carries a black box warning for potential heart failure risk
Long-term use should be monitored for bladder cancer risk
Monitor vitamin B12 levels periodically in long-term metformin users
Fully approved by CDSCO and compliant with Indian drug standards
SEIZMET GP 2 is manufactured in GMP-certified facilities ensuring high safety and efficacy standards
Patient Advice and Lifestyle Tips
Never skip meals while on this medicine to avoid hypoglycemia
Follow a balanced diabetic diet with controlled carbohydrate intake
Regular exercise is crucial for optimal effectiveness
Monitor blood sugar at home, especially during dose adjustments
Stay hydrated, and consult your doctor if you notice swelling, shortness of breath, or muscle weakness
Availability
SEIZMET GP 2 is widely available across pharmacies in India.
You can also order through registered hospital supply chains or authorized medical distributors.
For B2B partnerships or distributor enquiries, contact Steris Healthcare Pvt. Ltd.
Why Choose Steris Healthcare Pvt. Ltd. for Glimepiride Metformin and Pioglitazone Tablets?
When it comes to glimepiride metformin and pioglitazone tablets, quality, reliability, and affordability are paramount. Steris Healthcare Pvt. Ltd. offers:Pharmacologically accurate combinations
High-quality raw materials and packaging
GMP-compliant and ISO-certified facilities
Experienced pharmaceutical team and rigorous R&D
Competitive pricing with patient-first philosophy
Trust Steris Healthcare for evidence-based solutions that improve patient outcomes while maintaining affordability and safety.
Conclusion
The combination of glimepiride metformin and pioglitazone in SEIZMET GP 2 represents a powerful and balanced approach to managing Type 2 Diabetes. It addresses both insulin deficiency and resistance, offering improved glycemic control and long-term outcomes.
For patients and clinicians seeking a comprehensive antidiabetic solution, SEIZMET GP 2 is a reliable choice. Trust Steris Healthcare for safe, effective, and affordable diabetes management.
